

# **RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029**

<https://marketpublishers.com/r/R61227AE0CE0EN.html>

Date: July 2022

Pages: 200

Price: US\$ 4,175.00 (Single User License)

ID: R61227AE0CE0EN

## **Abstracts**

RWE Oncology Solutions Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029

The RWE oncology solutions market is expected to grow at a CAGR of 14.2% from 2022–2029 to reach \$1.65 billion by 2029.

After a comprehensive primary and secondary research and an in-depth analysis of the market scenario, this report provides insights into key industry drivers, restraints, challenges, and opportunities of the RWE oncology solutions market.

The growth of this market is driven by factors such as the rising prevalence of cancer, rapidly growing big data in healthcare, the shift from volume to value-based care, and the rising focus on personalized healthcare. Furthermore, emerging markets, rising focus on end-to-end RWE services, and rising adoption of mobile applications and wearable devices and AI in RWE are expected to provide significant growth opportunities for market players and new entrants in this market.

Based on component, in 2022, the real-world datasets segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the growing amount of medical data generated in hospitals,

increasing dependence on outcome-based studies on real-world data, and the rising demand for information regarding drug safety among payers, regulatory bodies, and providers.

Based on application, in 2022, the drug development & approvals segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the rising number of cancer cases, compelling pharmaceutical and biopharmaceutical companies to focus on drug development for cancer treatment. The effective deployment of RWE can significantly accelerate the pace of discovery, enable drug approvals, and help understand the impact of new oncology therapies, boosting the growth of this segment.

Based on end user, in 2022, the pharmaceutical & medical device companies segment is estimated to account for the largest share of the RWE oncology solutions market. The large market share of this segment is attributed to the importance of RWE studies in cancer drug development & approvals and the growing need to avoid costly drug recalls and assess drug performance in real-world settings.

An in-depth analysis of the geographical scenario of the RWE oncology solutions market provides detailed qualitative and quantitative insights into the five major geographies (North America, Asia-Pacific, Europe, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2022, North America is expected to command the largest share of the global RWE oncology solutions market, followed by Europe and Asia-Pacific.

Some of the key companies operating in the RWE oncology solutions market include IQVIA Holdings Inc. (U.S.), ICON plc (Ireland), PPD, Inc. (U.S.), SYNEOS HEALTH, INC. (U.S.), CLARIVATE PLC (U.S.), Medpace Holdings Inc. (U.S.), Symphony Innovation, LLC (U.S.), Clinigen Group plc (U.K.), Cognizant Technology Solutions Corporation (U.S.), Oracle Corporation (U.S.), PAREXEL International Corporation (U.S.), PerkinElmer, Inc. (U.S.), SAS Institute Inc. (U.S.), UnitedHealth Group Incorporated (U.S.), and Flatiron Health (U.S.).

Scope of the Report:

RWE Oncology Solutions Market, by Component

Real-world Datasets

Disparate Datasets

EMR/EHR/Clinical Data

Claims & Billing Data

Pharmacy Data

Cancer Registries

Other Disparate Datasets

Integrated Datasets

Real-world Consulting & Analytics Services

(Note: Other Disparate Datasets include data generated from mobile applications, wearable devices, and social media).

RWE Oncology Solutions Market, by Application

Drug Development & Approvals

Market Access & Reimbursement/Coverage Decisions

Post-market Surveillance

Medical Device Development & Approvals

Other Applications

(Note: Other Applications include regulatory and clinical decision-making).

RWE Oncology Solutions Market, by End User

Pharmaceutical, Biotechnology, and Medical Device Companies

Healthcare Payers

Healthcare Providers

Other End Users

(Note: Other end users include academic research institutions, patient advocacy groups, regulators, and health technology assessment agencies).

### RWE Oncology Solutions Market, by Geography

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe (RoE)

Asia-Pacific (APAC)

Japan

China

India

South Korea

Taiwan

Singapore

Rest of APAC (RoAPAC)

Latin America

Middle East & Africa

## Contents

### 1. INTRODUCTION

- 1.1. Market Definition
- 1.2. Market Ecosystem
- 1.3. Currency

### 2. RESEARCH METHODOLOGY

- 2.1. Research Process
- 2.2. Data Collection & Validation
  - 2.2.1. Secondary Research
  - 2.2.2. Primary Research
- 2.3. Market Assessment
  - 2.3.1. Market Size Estimation
    - 2.3.1.1. Bottom-up Approach
    - 2.3.1.2. Top-down Approach
    - 2.3.1.3. Growth Forecast
  - 2.3.2. Market Share Analysis

### 3. EXECUTIVE SUMMARY

### 4. MARKET INSIGHTS

- 4.1. Market Overview
- 4.2. Drivers
  - 4.2.1. Growing Burden of Cancer
  - 4.2.2. Rising Focus Towards Personalized Healthcare
  - 4.2.3. Delays in Drug Development and the Subsequent Increase in Development Costs
  - 4.2.4. Shift Towards Value-based Care
  - 4.2.5. Rapidly Growing Big Data in Healthcare
- 4.3. Restraints
  - 4.3.1. Reluctance to Rely on Real-world Studies
- 4.4. Opportunities
  - 4.4.1. Emerging Economies
  - 4.4.2. Rising Focus on End-to-end RWE Services
  - 4.4.3. Rising Adoption of Wearable Devices, Mobile Apps, and Artificial Intelligence in

## RWE

### 4.5. Challenges

4.5.1. Lack of Standardized Methodologies to Develop RWE

### 4.6. Impact Assessment of COVID-19

### 4.7. Key Market Trends

4.7.1. Growing Adoption of RWE in Drug Development and Commercialization

4.7.2. Rising Number of Consolidations

4.7.3. Improved Patient Outcomes and value Creation from Real-world Evidence

## **5. REGULATORY ANALYSIS— REAL-WORLD EVIDENCE (RWE) ONCOLOGY SOLUTIONS MARKET**

### 5.1. Introduction

### 5.2. North America

### 5.3. Europe

### 5.4. Asia-Pacific

### 5.5. Rest of the World

## **6. PRICING MODELS (EMR/GENOMIC/INTEGRATED DATASETS)**

### 6.1. Introduction

6.2. Pay Per Patient Record (Volume-based Pricing)

6.3. Pay Per Usage (Value-based Pricing)

6.4. Annual Subscription

## **7. GLOBAL RWE ONCOLOGY SOLUTIONS MARKET, BY COMPONENT**

### 7.1. Introduction

### 7.2. Datasets

7.2.1. Disparate Datasets

7.2.1.1. EMR/EHR/Clinical Data

7.2.1.2. Claims & Billing Data

7.2.1.3. Pharmacy Data

7.2.1.4. Cancer Registries

7.2.1.5. Other Disparate Datasets

7.2.2. Integrated Datasets

7.3. Consulting Services

## **8. GLOBAL RWE ONCOLOGY SOLUTIONS MARKET, BY APPLICATION**

*RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services),...*

- 8.1. Introduction
- 8.2. Drug Development & Approvals
- 8.3. Market Access & Reimbursement/Coverage Decisions
- 8.4. Medical Device Development & Approvals
- 8.5. Post-market Surveillance
- 8.6. Other Applications

## **9. GLOBAL RWE ONCOLOGY SOLUTIONS MARKET, BY END USER**

- 9.1. Introduction
- 9.2. Pharmaceutical, Biotechnology, and Medical Device Companies
- 9.3. Healthcare Payers
- 9.4. Healthcare Providers
- 9.5. Other End Users

## **10. RWE ONCOLOGY SOLUTIONS MARKET, BY GEOGRAPHY**

- 10.1. Introduction
- 10.2. North America
  - 10.2.1. U.S.
  - 10.2.2. Canada
- 10.3. Europe
  - 10.3.1. U.K.
  - 10.3.2. Germany
  - 10.3.3. France
  - 10.3.4. Italy
  - 10.3.5. Spain
- 10.4. Asia-Pacific
  - 10.4.1. Japan
  - 10.4.2. China
  - 10.4.3. India
  - 10.4.4. South Korea
  - 10.4.5. Taiwan
  - 10.4.6. Singapore
  - 10.4.7. Rest of Asia-Pacific
- 10.5. Latin America
- 10.6. Middle East & Africa



## **11. COMPETITIVE LANDSCAPE**

- 11.1. Introduction
- 11.2. Key Growth Strategies
- 11.3. Competitive Benchmarking
- 11.4. Market Share Analysis (2020)
  - 11.4.1. IQVIA Holdings, Inc. (U.S.)
  - 11.4.2. ICON plc (Ireland)
  - 11.4.3. PPD, Inc.

## **12. COMPANY PROFILES**

- 12.1. IQVIA HOLDINGS INC.
- 12.2. PPD, Inc.
- 12.3. ICON plc
- 12.4. Parexel International Corporation
- 12.5. IBM CORPORATION
- 12.6. UnitedHealth Group Incorporated
- 12.7. Flatiron Health
- 12.8. ORACLE CORPORATION
- 12.9. SAS Institute, Inc.
- 12.10. Anthem, Inc.
- 12.11. Clinigen Group plc
- 12.12. Cognizant Technology Solutions Corporation
- 12.13. PerkinElmer, Inc.

## **13. APPENDIX**

- 13.1. Questionnaire
- 13.2. Available Customization

## List Of Tables

### LIST OF TABLES

Table 1 Global RWE Oncology Solutions Market Drivers: Impact Analysis (2021–2028)

Table 2 Number of Persons Aged 65 Years or Over, by Region (2019 Vs. 2050)

Table 3 Total Per-study Cost (In USD Million), by Phase and Therapeutic Area

Table 4 Sources of Healthcare Data

Table 5 Global RWE Oncology Market Restraints: Impact Analysis (2021–2028)

Table 6 RWE in Latin American Countries

Table 7 Observed Indicative Prices of Real-World Data by Type (USD Per Patient Record)

Table 8 Global RWE Oncology Solutions Market Size, by Component, 2019–2029 (USD Million)

Table 9 Global Real-world Evidence Oncology Datasets Market Size, by Type, 2019–2029 (USD Million)

Table 10 Real-world Evidence Oncology Datasets Market Size, by Country/Region, 2019–2029 (USD Million)

Table 11 Global RWE Oncology Disparate Datasets Market Size, by Type, 2019–2029 (USD Million)

Table 12 RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million)

Table 13 RWE Oncology EMR/EHR/Clinical Data Market Size, by Country/Region, 2019–2029 (USD Million)

Table 14 RWE Oncology Claims & Billing Data Market Size, by Country/Region, 2019–2029 (USD Million)

Table 15 RWE Oncology Pharmacy Data Market Size, by Country/Region, 2019–2029 (USD Million)

Table 16 RWE Cancer Registries Data Market Size, by Country/Region, 2019–2029 (USD Million)

Table 17 Other RWE Oncology Disparate Datasets Market Size, by Country/Region, 2019–2029 (USD Million)

Table 18 RWE Oncology Integrated Datasets Market Size, by Country/Region, 2019–2029 (USD Million)

Table 19 RWE Oncology Consulting Services Market Size, by Country/Region, 2019–2029 (USD Million)

Table 20 Global RWE Oncology Solutions Market Size, by Application, 2019–2029 (USD Million)

Table 21 Global RWE Oncology Solutions Market Size for Market Access &

*RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services),...*

Reimbursement/Coverage Decisions, by Country/Region, 2019–2029 (USD Million)

Table 22 Oncology: Drugs in the R&D Pipeline

Table 23 Global RWE Oncology Solutions Market Size for Drug Development & Approvals, by Country/Region, 2019–2029 (USD Million)

Table 24 Global RWE Oncology Solutions Market Size for Medical Device Development & Approvals, by Country/Region, 2019–2029 (USD Million)

Table 25 Global RWE Oncology Solutions Market Size for Post-Market Surveillance, by Country/Region, 2019–2029 (USD Million)

Table 26 Global RWE Oncology Solutions Market Size for Other Applications, by Country/Region, 2019–2029 (USD Million)

Table 27 Global RWE Oncology Solutions Market Size, by End User, 2019–2029 (USD Million)

Table 28 Global RWE Oncology Solutions Market Size for Pharmaceutical, Biotechnology, and Medical Device Companies, by Country / Region, 2019–2029 (USD Million)

Table 29 Global RWE Oncology Market Size for Healthcare Payers, by Country/Region, 2019–2029 (USD Million)

Table 30 Global RWE Oncology Solutions Market Size for Healthcare Providers, by Country/Region, 2019–2029 (USD Million)

Table 31 Global RWE Oncology Market Size for Other End Users, by Country/Region, 2019–2029 (USD Million)

Table 32 Global RWE Oncology Solutions Market Size, by Country/Region, 2020–2029 (USD Million)

Table 33 North America: RWE Oncology Solutions Market Size, by Country, 2020–2029 (USD Million)

Table 34 North America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 35 North America: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 36 North America: RWE Oncology Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 37 North America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 38 North America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 39 U.S.: Estimated Number of New Cancer Cases (2021–2022)

Table 40 U.S.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 41 U.S.: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 42 U.S.: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 43 U.S.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 44 U.S.: RWE Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 45 Canada: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 46 Canada: RWE Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 47 Canada: RWE Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 48 Canada: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 49 Canada: RWE Oncology Market Size, by End User, 2020–2029 (USD Million)

Table 50 Europe: RWE Oncology Solutions Market Size, by Country, 2019–2029 (USD Million)

Table 51 Europe: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 52 Europe: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 53 Europe: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 54 Europe: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 55 Europe: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 56 U.K.: Conferences and Workshops on Real-world Evidence Solutions

Table 57 U.K.: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 58 U.K.: RWE Oncology Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 59 U.K.: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 60 U.K.: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 61 U.K.: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 62 Conferences, Symposia, and Workshops in Germany

Table 63 Germany: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 64 Germany: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 65 Germany: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 66 Germany: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 67 Germany: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 68 France: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 69 France: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 70 France: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 71 France: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 72 France: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 73 Italy: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 74 Italy: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 75 Italy: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 76 Italy: RWE Oncology Market Size, by Application, 2020–2029 (USD Million)

Table 77 Italy: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 78 Spain: RWE Oncology Market Size, by Component, 2020–2029 (USD Million)

Table 79 Spain: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 80 Spain: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 81 Spain: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 82 Spain: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 83 RoE: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 84 RoE: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029

(USD Million)

Table 85 RoE: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 86 RoE: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 87 RoE: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 88 Latin America: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 89 Latin America: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 90 Latin America: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 91 Latin America: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 92 Latin America: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 93 Middle East & Africa: RWE Oncology Solutions Market Size, by Component, 2020–2029 (USD Million)

Table 94 Middle East & Africa: RWE Oncology Solutions Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 95 Middle East & Africa: RWE Oncology Solutions Disparate Datasets Market Size, by Type, 2020–2029 (USD Million)

Table 96 Middle East & Africa: RWE Oncology Solutions Market Size, by Application, 2020–2029 (USD Million)

Table 97 Middle East & Africa: RWE Oncology Solutions Market Size, by End User, 2020–2029 (USD Million)

Table 98 Recent Developments, by Company, 2018–2021



## List Of Figures

### LIST OF FIGURES

Figure 1 Key Stakeholders

Figure 2 Research Process

Figure 3 Key Secondary Sources

Figure 4 Primary Research Techniques

Figure 5 Key Executives Interviewed

Figure 6 Breakdown of Primary Interviews (Supply-side & Demand-Side)

Figure 7 Market Size Estimation

Figure 8 Global RWE Oncology Solutions Market, by Component, 2022 Vs. 2029 (USD Million)

Figure 9 Global RWE Oncology Solutions Market, by Application, 2022 Vs. 2029 (USD Million)

Figure 10 Global RWE Oncology Solutions Market, by End User, 2022 Vs. 2029 (USD Million)

Figure 11 RWE Oncology Solutions Market, by Geography

Figure 12 Market Dynamics

Figure 13 Number of People with Chronic Conditions in the U.S. (2000-2030)

Figure 14 Percentage of Personalized Medicines Approved (2015-2020)

Figure 15 Asia-Pacific: Percent Share of Global Clinical Trial Activity (2012-2020)

Figure 16 Global RWE Oncology Solutions Market Size, by Component, 2022–2029 (USD Million)

Figure 17 U.S.: Number of E-Prescriptions, 2013–2020 (Billions)

Figure 18 Global RWE Oncology Solutions Market Size, by Application, 2022–2029 (USD Million)

Figure 19 Estimated Number of New Cancer Cases, by Region, 2020–2040 (In Millions)

Figure 20 Global RWE Oncology Solutions Market Size, by End User, 2022–2029 (USD Million)

Figure 21 Proportion of the Pharmaceutical Pipeline Which is in Development for Cancer, 2010–2021

Figure 22 Global RWE Oncology Solutions Market, by Region, 2022–2029 (USD Million)

Figure 23 North America: RWE Oncology Solutions Market Snapshot

Figure 24 Europe: RWE Oncology Solutions Market Snapshot

Figure 25 France: Share of Population Aged 65 & Above, 2010–2020

Figure 26 Italy: Share of Population Aged 65 Years & Above, 2015–2020

Figure 27 Key Growth Strategies Adopted by Leading Players (2018–2021)

Figure 28 Real-world Evidence Oncology Solutions: Competitive Benchmarking

Figure 29 Market Share Analysis: Real-world Evidence Oncology Solutions Industry (2021)

Figure 30 IQVIA HOLDINGS INC.: Financial Overview

Figure 31 PPD, Inc.: Financial Overview

Figure 32 ICON plc: Financial Overview

Figure 33 IBM corporation: Financial Overview

Figure 34 UnitedHealth Group Incorporated: Financial Overview

Figure 35 Oracle Corporation: Financial Overview

Figure 36 Anthem, Inc.: Financial Overview

Figure 37 Clinigen Group plc: Financial Overview

Figure 38 Cognizant Technology Solutions Corporation: Financial Overview

Figure 39 PerkinElmer, Inc.: Financial Overview



## I would like to order

Product name: RWE Oncology Market by Component (Datasets [EHR, Claims, Cancer Registries], Consulting & Analytics Services), Application (Drug Development, Approval, Market Access, Post-market Surveillance), End User (Pharma, Payer) - Global Forecast to 2029

Product link: <https://marketpublishers.com/r/R61227AE0CE0EN.html>

Price: US\$ 4,175.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/R61227AE0CE0EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970